Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Short term Debt (2016 - 2022)

Marker Therapeutics (MRKR) has disclosed Short term Debt for 6 consecutive years, with $2.5 million as the latest value for Q4 2022.

  • On a quarterly basis, Short term Debt changed N/A to $2.5 million in Q4 2022 year-over-year; TTM through Dec 2022 was $2.5 million, a N/A change, with the full-year FY2022 number at $2.5 million, changed N/A from a year prior.
  • Short term Debt was $2.5 million for Q4 2022 at Marker Therapeutics, down from $5.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $8.0 million in Q2 2022 to a low of $8000.0 in Q1 2018.
  • A 3-year average of $1.5 million and a median of $107000.0 in 2018 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: soared 1683.33% in 2018, then plummeted 55.78% in 2019.
  • Marker Therapeutics' Short term Debt stood at $49000.0 in 2018, then tumbled by 36.73% to $31000.0 in 2019, then soared by 7964.52% to $2.5 million in 2022.
  • Per Business Quant, the three most recent readings for MRKR's Short term Debt are $2.5 million (Q4 2022), $5.0 million (Q3 2022), and $8.0 million (Q2 2022).